Neumora Therapeutics (NMRA) Stock: Buy, Sell, or Hold?
NMRA - Neumora Therapeutics, Inc. Common Stock
$0.55
-0.05 (-7.75%)
▼
5d:
-21.77%
30d:
-58.65%
90d:
-67.07%
WAIT
LOW Confidence
Analysis Updated: Oct 1, 2026 12:00 AM ET
Earnings: Nov 05, 2026
Get Alerted When NMRA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: NMRA is down 21.8% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: NMRA is down 21.8% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: NMRA is currently trading at $0.55, which is considered oversold relative to its 30-day fair value range of $0.70 to $1.37.
Technical Outlook: Technically, NMRA is in a strong downtrend. The price is currently testing key support at $0.54. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 7.7% recently.
Market Sentiment: The stock scores a mixed 45/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $6.14 (+1016.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, NMRA is in a strong downtrend. The price is currently testing key support at $0.54. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 7.7% recently.
Market Sentiment: The stock scores a mixed 45/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $6.14 (+1016.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.70 -
$1.37
Company Quality Score
47/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-7.7%)
- BULLISH: Trading 1016.9% below Wall St target ($6.14)
- WARNING: Composite score 47/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.70 -
$1.37
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.54
Resistance Level
$0.81
Current Trend
Strong Downtrend
Technical data as of
Oct 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.82
Wall Street Target
$6.14
(+1016.9%)
Share & Embed Analysis
Last updated: October 02, 2026 3:42 AM ET
Data refreshes hourly during market hours. Next update: 4:42 AM
Data refreshes hourly during market hours. Next update: 4:42 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NMRA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 63 BUY |
|
RNA
Atrium Therapeutics, Inc… |
STRONG BUY
15 analysts |
$25 | 62 BUY |
|
VRDN
Viridian Therapeutics Inc |
STRONG BUY
16 analysts |
$37 | 57 HOLD |
|
SRRK
Scholar Rock Holding Corp |
STRONG BUY
10 analysts |
$70 | 70 BUY |
|
ARWR
Arrowhead Pharmaceutical… |
STRONG BUY
13 analysts |
$107 | 68 BUY |